# Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

> **NCT03941548** · PHASE2 · COMPLETED · sponsor: **Concert Pharmaceuticals** · enrollment: 66 (actual)

## Conditions studied

- Alopecia Areata

## Interventions

- **DRUG:** CTP-543
- **DRUG:** CTP-543 Matching Placebo

## Key facts

- **NCT ID:** NCT03941548
- **Lead sponsor:** Concert Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-24
- **Primary completion:** 2020-04-10
- **Final completion:** 2020-04-10
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2023-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03941548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03941548, "Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03941548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*